Deutsche Bank AG Takes Position in Xencor, Inc. $XNCR

Deutsche Bank AG acquired a new position in Xencor, Inc. (NASDAQ:XNCR) during the 2nd quarter, HoldingsChannel.com reports. The institutional investor acquired 119,822 shares of the biopharmaceutical company’s stock, valued at approximately $1,929,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. BVF Inc. IL boosted its holdings in Xencor by 160.3% in the 4th quarter. BVF Inc. IL now owns 7,133,720 shares of the biopharmaceutical company’s stock valued at $109,217,000 after purchasing an additional 4,393,579 shares during the period. Legal & General Group Plc grew its position in Xencor by 603.7% in the 3rd quarter. Legal & General Group Plc now owns 1,273,000 shares of the biopharmaceutical company’s stock worth $14,932,000 after purchasing an additional 1,092,095 shares during the last quarter. State Street Corp increased its holdings in shares of Xencor by 22.7% during the 4th quarter. State Street Corp now owns 4,507,254 shares of the biopharmaceutical company’s stock worth $69,006,000 after purchasing an additional 833,423 shares during the period. Johnson & Johnson bought a new position in shares of Xencor during the 2nd quarter worth about $12,043,798. Finally, Jefferies Financial Group Inc. raised its position in shares of Xencor by 620.4% during the fourth quarter. Jefferies Financial Group Inc. now owns 720,440 shares of the biopharmaceutical company’s stock valued at $11,030,000 after buying an additional 620,440 shares during the last quarter.

Xencor Stock Performance

Shares of Xencor stock opened at $26.06 on Friday. The firm has a market cap of $1.94 billion, a P/E ratio of -12.01 and a beta of 0.85. The firm’s 50-day simple moving average is $19.80 and its 200-day simple moving average is $14.77. Xencor, Inc. has a twelve month low of $7.83 and a twelve month high of $30.61.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.80) by $0.51. The firm had revenue of $51.22 million during the quarter, compared to analyst estimates of $18.89 million. Xencor had a negative net margin of 155.59% and a negative return on equity of 28.66%. The company’s quarterly revenue was up 17.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.41) earnings per share. On average, equities analysts forecast that Xencor, Inc. will post -3 earnings per share for the current fiscal year.

Analyst Ratings Changes

XNCR has been the subject of several research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xencor in a research note on Wednesday, June 24th. Wall Street Zen upgraded Xencor from a “strong sell” rating to a “hold” rating in a research note on Saturday, August 8th. Wedbush upped their price target on Xencor from $26.00 to $30.00 and gave the company an “outperform” rating in a report on Thursday, August 6th. Zacks Research upgraded Xencor from a “strong sell” rating to a “hold” rating in a research report on Monday, July 6th. Finally, Truist Financial decreased their price objective on Xencor from $29.00 to $27.00 and set a “buy” rating on the stock in a report on Tuesday, July 7th. Five analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $24.86.

Xencor Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.